The news is directly about Allogene Therapeutics. The Overweight rating suggests that JP Morgan expects the stock to outperform the market, which could be positive for the stock. However, the lowering of the price target could be seen as a negative signal, suggesting that JP Morgan expects less upside than before. The net impact on the stock price in the short term is uncertain, hence the neutral score.